Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity

Molecular Therapy

Volumn 26, Issue 1, 2018, Pages 289-303

  Paulk, Nicole K ^a   Pekrun, Katja ^a   Zhu, Erhua ^b   Nygaard, Sean ^c   Li, Bin ^c   Xu, Jianpeng ^a   Chu, Kirk ^a   Leborgne, Christian ^d   Dane, Allison P ^e   Haft, Annelise ^c   Zhang, Yue ^a   Zhang, Feijie ^a   Morton, Chris ^f   Valentine, Marcus B ^f   Davidoff, Andrew M ^f   Nathwani, Amit C ^e,g,h   Mingozzi, Federico ^d,i   Grompe, Markus ^c   Alexander, Ian E ^b   Lisowski, Leszek ^b,j   Kay, Mark A ^a   more..

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Genethon and INSERM U951 ^*  (France)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h NHS BLOOD AND TRANSPLANT   (United Kingdom)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j Biological Threat Identification and Countermeasure Centre of the Military   (Poland)

more..

Author keywords

AAV; evolution; hepatocyte; human; library; liver; neutralization; screen; transduction

Indexed keywords

IMMUNOGLOBULIN; CAPSID PROTEIN;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 5; ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOENGINEERING; CONTROLLED STUDY; DNA SHUFFLING; FEMALE; HEPATOCYTE TRANSPLANTATION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE EVASION; IN VIVO GENE TRANSFER; LIVER CELL; MALE; MOUSE; NONHUMAN; SANGER SEQUENCING; SERUM; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRUS CAPSID; VIRUS REPLICATION; XENOTRANSPLANTATION; ANIMAL; CHEMISTRY; DEPENDOPARVOVIRUS; GENE TRANSFER; GENE VECTOR; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GENETICS; LIVER; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION; XENOGRAFT;

ANIMALS; CAPSID PROTEINS; DEPENDOVIRUS; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GENETIC VECTORS; HEPATOCYTES; HETEROGRAFTS; HUMANS; LIVER; MALE; MICE; MODELS, MOLECULAR; PROTEIN CONFORMATION; TRANSDUCTION, GENETIC;

EID: 85031746439     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.09.021     Document Type: Article

References (60)

1. Nathwani, A.C., Reiss, U.M., Tuddenham, E.G., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371 (2014), 1994–2004.
2. Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12 (2006), 342–347.
3. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner-Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24 (2016), 1042–1049.
4. Lisowski, L., Dane, A.P., Chu, K., Zhang, Y., Cunningham, S.C., Wilson, E.M., Nygaard, S., Grompe, M., Alexander, I.E., Kay, M.A., Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506 (2014), 382–386.
5. Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D.C., Chowdary, P., Riddell, A., Pie, A.J., Harrington, C., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365 (2011), 2357–2365.
6. Li, C., Narkbunnam, N., Samulski, R.J., Asokan, A., Hu, G., Jacobson, L.J., Manco-Johnson, M.J., Monahan, P.E., Joint Outcome Study Investigators. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther. 19 (2012), 288–294.
7. Erles, K., Sebökovà P., Schlehofer, J.R., Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. Virol. 59 (1999), 406–411.
8. Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M.L., Wilson, J.M., Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin. Vaccine Immunol. 18 (2011), 1586–1588.
9. Ling, C., Wang, Y., Feng, Y.L., Zhang, Y.N., Li, J., Hu, X.R., Wang, L.N., Zhong, M.F., Zhai, X.F., Zolotukhin, I., et al. Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions. J. Integr. Med. 13 (2015), 341–346.
10. Liu, Q., Huang, W., Zhang, H., Wang, Y., Zhao, J., Song, A., Xie, H., Zhao, C., Gao, D., Wang, Y., Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Ther. 21 (2014), 732–738.
11. Liu, Q., Huang, W., Zhao, C., Zhang, L., Meng, S., Gao, D., Wang, Y., The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector. J. Med. Virol. 85 (2013), 1550–1556.
12. Mingozzi, F., Maus, M.V., Hui, D.J., Sabatino, D.E., Murphy, S.L., Rasko, J.E., Ragni, M.V., Manno, C.S., Sommer, J., Jiang, H., et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13 (2007), 419–422.
13. Grimm, D., Lee, J.S., Wang, L., Desai, T., Akache, B., Storm, T.A., Kay, M.A., In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82 (2008), 5887–5911.
14. Li, W., Asokan, A., Wu, Z., Van Dyke, T., DiPrimio, N., Johnson, J.S., Govindaswamy, L., Agbandje-McKenna, M., Leichtle, S., Eugene Redmond, D. Jr., et al. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol. Ther. 16 (2008), 1252–1260.
15. Kotterman, M.A., Schaffer, D.V., Engineering adeno-associated viruses for clinical gene therapy. Nat. Rev. Genet. 15 (2014), 445–451.
16. Gray, S.J., Blake, B.L., Criswell, H.E., Nicolson, S.C., Samulski, R.J., McCown, T.J., Li, W., Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18 (2010), 570–578.
17. Jang, J.H., Koerber, J.T., Kim, J.S., Asuri, P., Vazin, T., Bartel, M., Keung, A., Kwon, I., Park, K.I., Schaffer, D.V., An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells. Mol. Ther. 19 (2011), 667–675.
18. Davidoff, A.M., Gray, J.T., Ng, C.Y., Zhang, Y., Zhou, J., Spence, Y., Bakar, Y., Nathwani, A.C., Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol. Ther. 11 (2005), 875–888.
19. Nathwani, A.C., Gray, J.T., McIntosh, J., Ng, C.Y., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E.G., Davidoff, A.M., Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109 (2007), 1414–1421.
20. Nathwani, A.C., Gray, J.T., Ng, C.Y., Zhou, J., Spence, Y., Waddington, S.N., Tuddenham, E.G., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 107 (2006), 2653–2661.
21. Salganik, M., Aydemir, F., Nam, H.J., McKenna, R., Agbandje-McKenna, M., Muzyczka, N., Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes. J. Virol. 88 (2014), 1071–1079.
22. Chatterjee, S., Smith, L., and Wong, K. 2015. Adeno-associated virus vector variants for high efficiency genome editing and methods thereof. U.S. patent 62/209,862, filed August 25, 2015, and published July 13, 2017.
23. Xiao, W., Chirmule, N., Berta, S.C., McCullough, B., Gao, G., Wilson, J.M., Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73 (1999), 3994–4003.
24. Zincarelli, C., Soltys, S., Rengo, G., Rabinowitz, J.E., Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16 (2008), 1073–1080.
25. Azuma, H., Paulk, N., Ranade, A., Dorrell, C., Al-Dhalimy, M., Ellis, E., Strom, S., Kay, M.A., Finegold, M., Grompe, M., Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat. Biotechnol. 25 (2007), 903–910.
26. Opie, S.R., Warrington, K.H. Jr., Agbandje-McKenna, M., Zolotukhin, S., Muzyczka, N., Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77 (2003), 6995–7006.
27. Turunen, T.A., Kurkipuro, J., Heikura, T., Vuorio, T., Hytönen, E., Izsvák, Z., Ylä-Herttuala, S., Sleeping beauty transposon vectors in liver-directed gene delivery of LDLR and VLDLR for gene therapy of familial hypercholesterolemia. Mol. Ther. 24 (2016), 620–635.
28. Calcedo, R., Vandenberghe, L.H., Gao, G., Lin, J., Wilson, J.M., Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199 (2009), 381–390.
29. van der Marel, S., Comijn, E.M., Verspaget, H.W., van Deventer, S., van den Brink, G.R., Petry, H., Hommes, D.W., Ferreira, V., Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: implications for gene therapy. Inflamm. Bowel Dis. 17 (2011), 2436–2442.
30. Wang, L., Bell, P., Somanathan, S., Wang, Q., He, Z., Yu, H., McMenamin, D., Goode, T., Calcedo, R., Wilson, J.M., Comparative study of liver gene transfer with AAV vectors based on natural and engineered AAV capsids. Mol. Ther. 23 (2015), 1877–1887.
31. Kay, M.A., Selecting the best AAV capsid for human studies. Mol. Ther. 23 (2015), 1800–1801.
32. Zen, Z., Espinoza, Y., Bleu, T., Sommer, J.M., Wright, J.F., Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events. Hum. Gene Ther. 15 (2004), 709–715.
33. Grimm, D., Kern, A., Pawlita, M., Ferrari, F., Samulski, R., Kleinschmidt, J., Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6 (1999), 1322–1330.
34. Calcedo, R., Wilson, J.M., Humoral immune response to AAV. Front. Immunol., 4, 2013, 341.
35. Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M.F., Masurier, C., Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21 (2010), 704–712.
36. Halbert, C.L., Miller, A.D., McNamara, S., Emerson, J., Gibson, R.L., Ramsey, B., Aitken, M.L., Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum. Gene Ther. 17 (2006), 440–447.
37. Han, X., Ni, W., Cost-effectiveness analysis of Glybera for the treatment of lipoprotein lipase deficiency. Value Health, 18, 2015, A756.
38. Morrison, C., $1-million price tag set for Glybera gene therapy. Nat. Biotechnol. 33 (2015), 217–218.
39. Mingozzi, F., High, K.A., Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122 (2013), 23–36.
40. Grimm, D., Production methods for gene transfer vectors based on adeno-associated virus serotypes. Methods 28 (2002), 146–157.
41. Cunningham, S.C., Dane, A.P., Spinoulas, A., Logan, G.J., Alexander, I.E., Gene delivery to the juvenile mouse liver using AAV2/8 vectors. Mol. Ther. 16 (2008), 1081–1088.
42. Wilson, E.M., Bial, J., Tarlow, B., Bial, G., Jensen, B., Greiner, D.L., Brehm, M.A., Grompe, M., Extensive double humanization of both liver and hematopoiesis in FRGN mice. Stem Cell Res. (Amst.) 13:3 Pt A (2014), 404–412.
43. Huang, W., Johnston, W.A., Boden, M., Gillam, E.M., ReX: a suite of computational tools for the design, visualization, and analysis of chimeric protein libraries. Biotechniques 60 (2016), 91–94.
44. Weirather, J.L., de Cesare, M., Wang, Y., Piazza, P., Sebastiano, V., Wang, X.J., Buck, D., Au, K.F., Comprehensive comparison of Pacific Biosciences and Oxford Nanopore Technologies and their applications to transcriptome analysis. F1000Res., 6, 2017, 100.
45. Jiao, X., Zheng, X., Ma, L., Kutty, G., Gogineni, E., Sun, Q., Sherman, B.T., Hu, X., Jones, K., Raley, C., et al. A benchmark study on error assessment and quality control of CCS reads derived from the PacBio RS. J. Data Mining Genomics Proteomics, 4, 2013, 16008.
46. Edgar, R.C., MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32 (2004), 1792–1797.
47. Stamatakis, A., Ludwig, T., Meier, H., RAxML-III: a fast program for maximum likelihood-based inference of large phylogenetic trees. Bioinformatics 21 (2005), 456–463.
48. Barzel, A., Paulk, N.K., Shi, Y., Huang, Y., Chu, K., Zhang, F., Valdmanis, P.N., Spector, L.P., Porteus, M.H., Gaensler, K.M., Kay, M.A., Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature 517 (2015), 360–364.
49. Namekawa, S.H., Payer, B., Huynh, K.D., Jaenisch, R., Lee, J.T., Two-step imprinted X inactivation: repeat versus genic silencing in the mouse. Mol. Cell. Biol. 30 (2010), 3187–3205.
50. Huch, M., Dorrell, C., Boj, S.F., van Es, J.H., Li, V.S., van de Wetering, M., Sato, T., Hamer, K., Sasaki, N., Finegold, M.J., et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature 494 (2013), 247–250.
51. Dorrell, C., Tarlow, B., Wang, Y., Canaday, P.S., Haft, A., Schug, J., Streeter, P.R., Finegold, M.J., Shenje, L.T., Kaestner, K.H., Grompe, M., The organoid-initiating cells in mouse pancreas and liver are phenotypically and functionally similar. Stem Cell Res. (Amst.) 13 (2014), 275–283.
52. Mingozzi, F., Chen, Y., Edmonson, S.C., Zhou, S., Thurlings, R.M., Tak, P.P., High, K.A., Vervoordeldonk, M.J., Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther. 20 (2013), 417–424.
53. Meliani, A., Leborgne, C., Triffault, S., Jeanson-Leh, L., Veron, P., Mingozzi, F., Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system. Hum. Gene Ther. Methods 26 (2015), 45–53.
54. Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., Chapman, M.S., The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99 (2002), 10405–10410.
55. Dane, A.P., Wowro, S.J., Cunningham, S.C., Alexander, I.E., Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes. Gene Ther. 20 (2013), 460–464.
56. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23 (2015), 1867–1876.
57. D'Avola, D., López-Franco, E., Sangro, B., Pañeda, A., Grossios, N., Gil-Farina, I., Benito, A., Twisk, J., Paz, M., Ruiz, J., et al. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J. Hepatol. 65 (2016), 776–783.
58. uniQure. December 3, 2016. Press release: uniQure announces first clinical data from second dose cohort of AMT-060 in ongoing phase I/II trial in patients with severe hemophilia B. https://globenewswire.com/news-release/2016/12/03/894861/0/en/uniQure-Announces-First-Clinical-Data-From-Second-Dose-Cohort-of-AMT-060-in-Ongoing-Phase-I-II-trial-in-Patients-with-Severe-Hemophilia-B.html.
59. Pañeda, A., Vanrell, L., Mauleon, I., Crettaz, J.S., Berraondo, P., Timmermans, E.J., Beattie, S.G., Twisk, J., van Deventer, S., Prieto, J., et al. Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. Hum. Gene Ther. 20 (2009), 908–917.
60. Nakai, H., Fuess, S., Storm, T.A., Muramatsu, S., Nara, Y., Kay, M.A., Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J. Virol. 79 (2005), 214–224.